Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Intravenous ketamine administration for treatment-resistant depression with rapid onset of action.
The most widely used and evidence-based psychedelic therapy form. Racemic ketamine (0.5mg/kg IV over 40 minutes) or esketamine (Spravato, intranasal) is administered in a clinical setting under medical supervision. Standard treatment involves 6 induction infusions over 2-3 weeks followed by maintenance therapy.
NMDA receptor antagonism, glutamate surge, AMPA potentiation, BDNF upregulation, rapid synaptogenesis in PFC and hippocampus.